News of Cabozantinib

The US Food and Drug Administration (FDA) has approved a new indication for Cabozantinib for the treatment of locally advanced or metastatic differentiated thyroid cancer (DTC) in adult and pediatric patients aged 12 years and older.

These patients experienced disease progression after receiving targeted therapy for vascular endothelial growth factor receptor (VEGFR) and were insensitive to radioactive iodine therapy. This approval is based on the results of a randomized, double-blind, placebo-controlled, multicenter clinical trial.